canyon landscape

Pridopidine for Levodopa-Induced Dyskinesia in Parkinson’s Disease

This is a multicenter, randomized, double-blind, placebo-controlled, three-arm parallel group study to evaluate the efficacy, safety, and pharmacokinetics (PK) of pridopidine versus placebo for the treatment of Levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease.

Status
Open and enrolling subjects.
Location
Phoenix, Arizona
Age Range
  • 30-85
Total Participants
135
Primary Sponsor
Prilenia